Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Capital Expenditures (2020 - 2025)

Sight Sciences has reported Capital Expenditures over the past 6 years, most recently at -$156000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$156000.0 for Q4 2025, down 213.87% from a year ago — trailing twelve months through Dec 2025 was $224000.0 (down 41.82% YoY), and the annual figure for FY2025 was $224000.0, down 41.82%.
  • Capital Expenditures for Q4 2025 was -$156000.0 at Sight Sciences, down from $170000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for SGHT hit a ceiling of $342000.0 in Q2 2022 and a floor of -$156000.0 in Q4 2025.
  • Median Capital Expenditures over the past 5 years was $157000.0 (2021), compared with a mean of $167526.3.
  • Peak annual rise in Capital Expenditures hit 233.33% in 2025, while the deepest fall reached 213.87% in 2025.
  • Sight Sciences' Capital Expenditures stood at $157000.0 in 2021, then fell by 17.83% to $129000.0 in 2022, then skyrocketed by 104.65% to $264000.0 in 2023, then crashed by 48.11% to $137000.0 in 2024, then crashed by 213.87% to -$156000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$156000.0 (Q4 2025), $170000.0 (Q3 2025), and $210000.0 (Q2 2025) per Business Quant data.